Diagnostics

  • SoloHealth realigns to focus on wellness plans for major employers

    DULUTH, Ga. — As part of a realignment to "focus on wellness plans for major employers," SoloHealth founder Bart Foster has stepped down as CEO of the company to assume a new role as chief strategy officer, according to a report in the Atlanta Business Chronicle published Thursday. 

    Chairman Larry Gerdes will assume the role of CEO. The move will capitalize on the strengths of Foster — sales and strategy — Gerdes told the Chronicle. 

  • C&D gets FDA clearance for advanced pregnancy test kit, launches new app

    EWING, N.J. — Church & Dwight on Tuesday announced that the Food and Drug Administration has cleared the First Response Gold Digital Pregnancy Test to determine if a woman is pregnant up to six days before her missed period and with more than 99% accuracy from the day of her expected period. In addition, the First Response Early Result Pregnancy Test, which was previously cleared to determine if a woman is pregnant up to six days before her missed period, also has been FDA-cleared to detect pregnancy with more than 99% accuracy from the day of her expected period. 

  • New study suggests blood pressure should be measured in both arms

    PHILADELPHIA — New research published in the March issue of the American Journal of Medicine suggests that there is an association between a difference in interarm systolic blood pressure and a significant increased risk for future cardiovascular events, leading researchers to recommend expanded clinical use of interarm blood-pressure measurement.

  • Omron launches Alvita Ultimate Pedometer

    LAKE FOREST, Ill. — Omron Healthcare on Monday launched the Alvita Ultimate Pedometer, which replaces its HJ-112 model. The new pedometer uses Tri-Axis technology to count steps accurately almost anywhere the device is positioned, including the hip, pocket or a purse. It has four activity modes for both regular and aerobic activities, and stores up to seven days of information on the display.

  • ECG monitor AliveCor granted OTC status

    SAN FRANCISCO — AliveCor on Monday announced that the Food and Drug Administration has granted the company over-the-counter clearance for the AliveCor Heart Monitor, a single-channel ECG (electrocardiogram) recorder, previously available by prescription only. The device is available now for pre-order purchase with shipments beginning in March.

X
This ad will auto-close in 10 seconds